Abstract
Many studies have shown the presence of minimal residual disease (MRD) following therapy for childhood acute lymphoblastic leukemia (ALL) to be an important prognostic marker. We have also shown a significant relationship between survival outcomes in patients enrolled in the previous ALL 911 study and molecular MRD levels 5 weeks (time point 1, TP1) and 12 weeks (TP2) following the initiation of chemotherapy (
Leukaemia and Lymphoma
2002
; 43
: 1001
Leukaemia and Lymphoma
2002
; 43
: 1001
[Acknowledgment: This study was partly supported by grants from the Children’s Cancer Association of Japan (CCAJ)].
Disclosures: No relevant conflicts of interest to declare.
Author notes
Corresponding author
2008, The American Society of Hematology
2008
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal